KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Debt to Equity (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Debt to Equity for 13 consecutive years, with $2.1 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Debt to Equity changed N/A year-over-year to $2.1, compared with a TTM value of $2.1 through Jun 2025, changed N/A, and an annual FY2024 reading of $1.16, changed N/A over the prior year.
  • Debt to Equity was $2.1 for Q2 2025 at Travere Therapeutics, roughly flat from $2.09 in the prior quarter.
  • Across five years, Debt to Equity topped out at $2.1 in Q2 2025 and bottomed at -$2.25 in Q3 2024.
  • Average Debt to Equity over 5 years is $0.32, with a median of $0.06 recorded in 2023.
  • The sharpest move saw Debt to Equity tumbled 70.27% in 2021, then skyrocketed 566.92% in 2022.
  • Year by year, Debt to Equity stood at $0.02 in 2021, then soared by 566.92% to $0.16 in 2022, then crashed by 63.74% to $0.06 in 2023, then soared by 1862.55% to $1.16 in 2024, then skyrocketed by 80.82% to $2.1 in 2025.
  • Business Quant data shows Debt to Equity for TVTX at $2.1 in Q2 2025, $2.09 in Q1 2025, and $1.16 in Q4 2024.